[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"in-vitro-fertilization-ivf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:in-vitro-fertilization-ivf":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,83,113,138,168,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100638637","the-impact-of-myomectomy-on-ivf-outcomes-a-multicenter-randomized-controlled-trial-100638637",false,"NCT07578623","The Impact of Myomectomy on IVF Outcomes: A Multicenter Randomized Controlled Trial","MIO","Inclusion Criteria:\n\n* Female patients aged 20 years or older and younger than 40 years.\n* Primary infertility or secondary infertility. Infertility factors may include male partner factors, ovulatory disorders, tubal factors, endometriosis, other non-uterine corpus disease factors, or unexplained infertility.\n* Pelvic MRI indicating intramural fibroids: FIGO type 4-6; the largest fibroid has a maximum diameter of at least 4 cm and less than 6 cm; a total of no more than two fibroids measuring 4-6 cm; fibroids smaller than 4 cm may be disregarded.\n* Meets indications for IVF and is willing to undergo IVF treatment.\n\nExclusion Criteria:\n\n* Infertility factors related to diseases of the uterine corpus, including but not limited to adenomyosis, intrauterine adhesions, endometritis, submucosal fibroids, and multiple endometrial polyps. A single endometrial polyp 1 cm or smaller does not require exclusion.\n* Coexisting malignant or borderline tumors of the reproductive system, or other malignant tumors that are untreated or still under treatment.\n* Active pelvic inflammatory disease.\n* Previous cytotoxic therapy or pelvic\u002Fabdominal radiotherapy or chemotherapy.\n* Previous surgery of the uterine corpus, including but not limited to myomectomy, uterine wedge resection, uterine artery embolization, tumor coagulation of the uterine corpus such as high-intensity focused ultrasound or electrocoagulation, and hysteroscopic myomectomy. Prior hysteroscopy, diagnostic curettage, or hysteroscopic polypectomy does not require exclusion.\n* Expected inability to complete follow-up.","FEMALE","20 Years","40 Years",{"count":20,"type":21},792,"ESTIMATED","INTERVENTIONAL",[24],"NA","Uterine fibroids are the most common benign tumors of the female reproductive system and are frequently encountered in women of reproductive age. Although many fibroids are asymptomatic, 5%-10% of women with infertility have coexisting fibroids, and in a small proportion fibroids may be the only identifiable cause of infertility. Fibroids may impair fertility by altering uterine anatomy, affecting uterine blood supply, inducing abnormal uterine contractions or endometrial peristalsis, and impairing endometrial receptivity.\n\nThe impact of fibroids on fertility depends strongly on their type, size, number, and relationship to the uterine cavity. Submucosal fibroids clearly reduce clinical pregnancy, implantation, and live birth rates and increase miscarriage risk in patients undergoing assisted reproductive technology. In contrast, the effect of intramural fibroids, especially those that do not distort the uterine cavity, remains controversial. Some studies suggest no significant effect on IVF outcomes, whereas others report reduced clinical pregnancy and live birth rates. Evidence also suggests that fibroids located close to the endometrium or measuring ≥4 cm may be more clinically relevant for assisted reproduction.\n\nCurrent guidelines differ regarding whether infertile women with fibroids should undergo myomectomy before IVF. Chinese expert consensus recommends myomectomy for women preparing for pregnancy when fibroid diameter is ≥4 cm, whereas other international guidelines emphasize individualized management and note the lack of high-quality evidence. Existing studies are limited by small sample size, retrospective design, and inconsistent inclusion criteria. Therefore, whether myomectomy improves IVF outcomes in women with non-cavity-distorting intramural or subserosal fibroids remains uncertain.\n\nImaging plays an important role in fibroid assessment. Transvaginal ultrasound is widely used because it is inexpensive and accessible, but it has limitations in accurately localizing fibroids and detecting small lesions. Pelvic MRI provides more accurate evaluation of fibroid location, size, and relationship to the myometrium and endometrium, and is particularly useful for study eligibility assessment.\n\nThis multicenter randomized controlled trial is designed to evaluate whether myomectomy improves IVF outcomes in infertile women with FIGO type IV, V, or VI uterine fibroids measuring 4-6 cm. The study will compare IVF outcomes between women who undergo myomectomy before IVF and women who proceed directly to IVF without fibroid removal. The main objective is to determine whether surgical removal of these fibroids improves cumulative live birth after IVF.",[27,28,29],"Infertility","In Vitro Fertilization (IVF)","Uterine Myomas, Leiomyomas, or Fibromas","NOT_YET_RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-11","ACTUAL",{"date":36,"type":21},"2026-05-01",{"date":38,"type":21},"2029-06-01",{"name":40,"class":41},"Peking Union Medical College Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100612720","levothyroxine-treatment-and-ivf-outcomes-in-women-with-subclinical-hypothyroidism-a-target-trial-emulation-100612720","NCT07257250","Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","Effectiveness of Levothyroxine Treatment on In Vitro Fertilization and Pregnancy Outcome in Women With Subclinical Hypothyroidism and Infertility: A Target Trial Emulation","LESI","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosed with subclinical hypothyroidism (TSH 4.2-\\\u003C10 mIU\u002FL with FT4 0.92-1.68 ng\u002FdL).\n* Undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) followed by frozen embryo transfer (FET).\n\nExclusion Criteria:\n\n* Overt hypothyroidism (TSH ≥10 mIU\u002FL and FT4 ≤0.92 ng\u002FdL).\n* Current or recent (within 1 month) use of drugs affecting thyroid function (levothyroxine, amiodarone, methimazole, propylthiouracil).","18 Years","45 Years",{"count":53,"type":21},900,"OBSERVATIONAL","Subclinical hypothyroidism (SCH) is defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (fT4) levels. It affects approximately 5-7% of women of reproductive age and may negatively influence outcomes of assisted reproductive technology (ART). During controlled ovarian stimulation, rising estradiol increases thyroxine-binding globulin and thyroid hormone requirements. These physiological changes, combined with increased metabolic demand in early pregnancy, may worsen SCH and contribute to adverse outcomes such as miscarriage, preterm birth, and hypertensive disorders of pregnancy.\n\nAlthough levothyroxine (LT4) is routinely used to treat overt hypothyroidism, evidence for its benefit in SCH, especially among infertile women undergoing In Vitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI) with frozen embryo transfer (FET), remains inconclusive. Some trials and meta-analyses have shown reductions in miscarriage and neonatal mortality, while others have found no improvement in ART or obstetric outcomes.\n\nThis study aims to evaluate the effectiveness of levothyroxine therapy on IVF\u002FFET outcomes and subsequent pregnancy results in women with subclinical hypothyroidism and infertility. This retrospective cohort study will emulate the target trial to evaluate whether LT4 treatment, titrated to achieve a pre-transfer TSH \\\u003C 2.5 mIU\u002FL, improves implantation, live birth, and obstetric outcomes compared with expectant management.",[57,27,58,28,59,60],"Subclinical Hypothyroidism","Assisted Reproductive Technology","Intracytoplasmic Sperm Injection","Frozen Embryo Transfer (FET)",[62,57,27,63,64,65,66,67,58,68,69,70,71],"Levothyroxine","Thyroid Disorders","IVF","ICSI","Frozen Embryo Transfer","FET","Live Birth","Miscarriage","Pregnancy Outcomes","Thyroid Autoimmunity","RECRUITING","2026-01-13",{"date":75,"type":34},"2026-01-14",{"date":77,"type":34},"2019-01-01",{"date":79,"type":21},"2026-03-30",{"name":81,"class":41},"Mỹ Đức Hospital",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":50,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100382129","use-of-artificial-intelligence-for-clinical-assessment-of-assisted-reproductive-techniques-and-ivf-outcomes-100382129","NCT04255615","Use of Artificial Intelligence for Clinical Assessment of Assisted Reproductive Techniques and IVF Outcomes","The Use of Artificial Intelligence for Clinical Assessment of Assisted Reproductive Techniques and IVF Outcomes","AI in ART","Inclusion Criteria:\n\n* All patients undergoing ovarian stimulation (including OI and IVF cycles)\n* Treatment for fresh embryo transfer and cryopreservation of oocytes or embryos upfront\n* Healthy male partners of the female subjects who agree to be part of the study.\n\nExclusion Criteria:\n\n* None",true,"ALL","89 Years",{"count":95,"type":21},4000,[24],"The use of machine learning techniques using an artificial intelligence tool is proposed to analyze clinical data to predict best possible IVF\u002FART outcomes. This tool has been utilized to accurately predict embryo quality here at Cornell. Utilizing this tool to assess objective clinical findings and predict outcomes of assisted reproductive techniques is sought, with the ultimate goal of an automated tool to reduce implicit physician bias. Within this goal, using this tool to objectively and accurately assess baseline ovarian reserve at the start of an ART cycle is proposed, using 3D sonography to image the ovary and artificial intelligence tool to objectively identify baseline antral follicle counts.",[27,99,100],"in Vitro Fertilization (IVF)","ART",[102],"Artificial Intelligence","2025-12-17",{"date":105,"type":34},"2025-12-24",{"date":107,"type":34},"2020-02-12",{"date":109,"type":21},"2029-09-30",{"name":111,"class":41},"Weill Medical College of Cornell University",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":91,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100613653","phase-4-dual-trigger-with-hcg-and-gnrh-agonist-on-thawed-modified-natural-cycle-embryo-transfer-100613653","NCT07269392","Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer","Impact of Dual Trigger Using Recombinant Human Chorionic Gonadotropin (HCG) and Gonadotropin-releasing Hormone (GnRH) Agonist on Thawed Modified Natural Cycle Outcomes: an Open-label Multi-center Randomized Controlled Trial.","Inclusion Criteria:\n\n1\\. 24\\\u003C= Age \\\u003C 45 patient undergo mNC-FET\n\nExclusion Criteria:\n\n1\\. Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp \\>1cm)","25 Years","44 Years",{"count":123,"type":21},170,[125],"PHASE4","Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.",[28,128],"Embryo Transfer","2025-12-08",{"date":131,"type":34},"2025-12-16",{"date":133,"type":21},"2026-01-01",{"date":135,"type":21},"2029-12-31",{"name":137,"class":41},"National Taiwan University Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":18,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":112},"100601294","phase-3-hcg-priming-in-women-with-diminished-ovarian-reserve-100601294","NCT07108621","hCG Priming in Women With Diminished Ovarian Reserve","Eight Weeks of Low Dose hCG Priming in Women With Diminished Ovarian Reserve Undergoing IVF\u002FICSI - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-40 (both inclusive)\n* Regular menstrual cycle (23-35 days)\n* 1.-5. IVF\u002FICSI cycle at inclusion\n* AMH \\\u003C 6.29 pmol\u002FL (Elecsys® AMH assay)\n\nExclusion Criteria:\n\n* Uterine malformations or hydrosalpinx\n* Submucosal uterine myomas\n* Uterine polyps\n* Allergy to standard IVF\u002FICSI medication\n* Endometriosis stage III-IV\n* Preimplantation genetic testing\n* Testicular sperm aspiration\u002Fextraction\n* Ovarian enlargement or cysts (other than normally occurring corpora luteae)\n* Gynaecological haemorrhages of unknown aetiology\n* Known severe comorbidity\\*\n\n  * i.e., Insulin dependent diabetes mellitus, non-insulin dependent diabetes mellitus, gastrointestinal, cardiovascular, thromboembolic (including active thromboembolic disorders), pulmonary, liver or kidney diseases, HIV or Hepatitis B\u002FC, dysregulated thyroid disease, tumors of the hypothalamus or pituitary gland or ovarian, uterine, or mammary carcinoma.",{"count":146,"type":21},80,[148],"PHASE3","The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)\u002Fintracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. To incorporate the strengths of a randomized controlled trial design, women will be randomized after their first ICSI treatment to receive either hCG or placebo in a double-blinded design during an eight-week priming period preceding their second ICSI treatment. The primary outcome is the number of oocytes retrieved in the second ICSI treatment.",[151,152,28],"Infertility, Female","Ovarian Reserve",[154,155,156,157,158],"hCG priming","Androgen priming","Diminished ovarian reserve","In vitro fertilization (IVF)","Controlled ovarian stimulation","2025-09-10",{"date":161,"type":34},"2025-09-17",{"date":163,"type":21},"2025-09",{"date":165,"type":21},"2031-03-31",{"name":167,"class":41},"Kristine Loessl",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100573090","direct-warming-frozen-embryo-transfer-outcomes-in-assisted-reproductive-technology-100573090","NCT06741748","Direct Warming Frozen Embryo Transfer Outcomes in Assisted Reproductive Technology","A Pragmatic, Multi-centre, Double-blinded, Two-arm Randomized Controlled Trial on a Direct Warming Frozen Embryo Transfer in Assisted Reproductive Technologies Treatment Outcome","DW-FET-RCT","Inclusion Criteria:\n\n* Plan to undergo single embryo transfer (SET) during the FET cycle.\n* Age between 18 and 45 years.\n* Patients with at least one high-quality blastocyst available for transfer.\n* Patients who have provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with repeated implantation failure (RIF) or recurrent miscarriage (RM).\n* Patients with known uterine anomalies or significant uterine pathology (e.g., fibroids, polyps).\n* Patients who are unwilling or unable to provide informed consent.",{"count":177,"type":21},578,[24],"The goal of this clinical trial is to evaluate whether the direct warming method for frozen embryo transfers (FET) can improve live birth and pregnancy outcomes in women aged 18-45 undergoing IVF treatments. The main questions it aims to answer are:\n\n* Does the direct warming method achieve a similar or higher clinical success rate for FET compared to the conventional multi-step method?\n* Is the direct warming method more cost-effective than the conventional method?\n\nResearchers will compare the direct warming method to the conventional multi-step method to see if the former leads to better pregnancy outcomes and reduced procedural time.\n\nParticipants will:\n\n* Undergo either the one-step or conventional embryo thawing procedure.\n* Complete standard clinical follow-ups for pregnancy, including ultrasound scans and pregnancy tests.",[60,181,28,182,183],"Assisted Reproductive Techniques","Cryopreservation of Embryos","Pregnancy Outcome After in Vitro Fertilization (IVF)",[185,66,186,187,188,189,190],"Direct Warming Method","Assisted Reproductive Technologies","Cryopreservation","Cost-effectiveness in ART","Embryo Warming","In Vitro Fertilization","2025-03-06",{"date":193,"type":34},"2025-03-11",{"date":195,"type":21},"2025-09-01",{"date":197,"type":21},"2027-10-31",{"name":199,"class":41},"Chinese University of Hong Kong",3,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100578543","assessment-of-some-metabolic-and-hematological-markers-in-women-exposed-to-in-vitro-fertilization-100578543","NCT06812663","Assessment of Some Metabolic and Hematological Markers in Women Exposed to in Vitro Fertilization","Inclusion Criteria:\n\n* Women aged 30 years of age and above,\n* presenting with any infertility concern\n* BMI 18.5-38 kg\u002Fm2\n\nExclusion Criteria:\n\n* current or past history of diabetes mellitus, thyroid dysfunction and any other chronic medical condition such as hepatic, renal, respiratory, haematological and cardiovascular disease. Other exclusion criteria included use of any therapy that may affect glucose homeostasis, thyroid and\u002For lipid profile","30 Years",{"count":209,"type":21},115,"Assisted reproductive technologies (ART) represent commonly utilized management strategies for infertility with multifactorial causes (including genetically predisposed diseases). Amongst ART, in vitro fertilization (IVF) is the most popular. IVF treatment may predispose the mother to increased risks and complications during pregnancy, and there may be adverse fetal outcomes. Hormonal therapies, including oral contraceptives, may impair glucose and lipid metabolism, and promote insulin resistance and inflammation.\n\nIn vitro fertilization therapy induces weight gain and impairment in glucose, insulin and lipid homeostasis in failed IVF. Improvement of glucose homeostasis, decrease in thyroid profile and increase in lipid profile in clinical pregnancy are likely a pregnancy-related effect.\n\nHyperglycemic pregnant women were proven to have a high prevalence of caesarean section, preterm delivery, low one-minute Apgar score, respiratory distress syndrome, neonatal jaundice, admission to the neonatal ICU, infants born large for gestational age (LGA), macrosomia.preconception abnormal glucose metabolism may increase the risk of adverse neonatal outcomes in PCOS women. The monitoring and management of preconception glucose homeostasis and IR are essential methods of improving the neonatal outcomes of PCOS women.\n\nSuccessful implantation and placentation require well-balanced inflammation and immune tolerance. Apart from white blood cells, the role of platelets in the release of mediators that cause local changes in the inflammatory process is very relevant.\n\nIncreased levels of CBC inflammation markers may have a negative impact on IVF outcomes among nonobese women with UI.\n\nSuccessful embryo implantation requires a favorable endometrium, good-quality embryos and delicate coordination between the embryo and endometrium. The tightly controlled inflammatory response in the window of receptivity is essential for successful implantation and growing evidence suggests that chronic inflammation is associated with RIF.\n\nthe aim of this study -To explore effects of IVF therapies on metabolic and endocrinal parameters in IVF-conceived pregnancy and its relation to outcome.\n\n2- To investigate whether there could be an association between hematological infammatory markers and in vitro fertilization (IVF) success",[28],[213],"metabolic and hematological markers","2025-02-03",{"date":216,"type":34},"2025-02-06",{"date":218,"type":21},"2025-03-01",{"date":220,"type":21},"2027-05-01",{"name":222,"class":41},"Assiut University"]